Welcome to LookChem.com Sign In|Join Free

CAS

  • or

179324-69-7

Post Buying Request

179324-69-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

179324-69-7 Usage

Description

Bortezomib, also known as Velcade, is a modified dipeptidyl boronic acid and the first proteasome inhibitor approved by the US FDA for the treatment of multiple myeloma, a blood cancer. It is a potent, highly selective, and reversible inhibitor of the 26S proteasome, a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Bortezomib is capable of inhibiting the mammalian 26S proteasome, which plays a crucial role in regulating intracellular protein concentrations to maintain cellular homeostasis. The disruption of 26S proteasome function by Bortezomib leads to the accumulation of ubiquitylated proteins, disrupting cell-signaling processes and cell growth, particularly affecting the transcription factor NF-kB.

Uses

Used in Oncology:
Bortezomib is used as an antineoplastic agent for the treatment of multiple myeloma, a cancer that arises from plasma cells. It controls the growth of cancer cells by inhibiting the 26S proteasome, which is essential for the degradation of proteins marked by ubiquitin. This inhibition disrupts normal cellular homeostasis, leading to cytotoxic effects on various kinds of cancer cells.
Used in the Treatment of Relapsed Multiple Myeloma:
Bortezomib is used as a therapeutic agent for patients with relapsed multiple myeloma who have received at least two prior therapies and demonstrated disease progression on their most recent therapy. In a study, about twenty-eight percent of these patients showed a response to Bortezomib, with the response lasting a median time of one year.
Used in the Treatment of Mantle Cell Lymphoma:
Bortezomib is also indicated for the treatment of mantle cell lymphoma, a type of non-Hodgkin lymphoma. It has shown efficacy in this application due to its ability to inhibit the 26S proteasome, which plays a role in the survival and proliferation of cancer cells.
Used in Cancer Research:
Bortezomib is used as a research tool in the study of the proteasome's role in various cellular processes, including cell cycle regulation, gene expression, and inflammatory processes. Its ability to inhibit the 26S proteasome makes it a valuable compound for investigating the mechanisms of cancer development and progression.

Drug for Cancer treatment

Bortezomib is a drug for treatment of hematopoietic malignancies with the appearance being white or white-like crystalline powder. It is easily soluble in dimethyl sulfoxide, ethanol, but insoluble in aqueous solution. This product is the reversible inhibitor of the mammal cell 26S proteasome chymotrypsin-like activity. 26S proteasome is a large protein complex which can degrade ubiquitin. Ubiquitin proteasome pathway plays an important role in regulation of the intracellular concentration of specific proteins in order to maintain the stability of the intracellular environment. Proteolytic affects intracellular multi-level signalling cascade. The disruption of the normal intracellular environment can lead to cell death while the inhibition of the 26S proteasome can prevent the hydrolysis of specific proteins. In vitro tests have proved bortezomib exhibits cytotoxicity to multiple types of cancer cells. The in vivo models of preclinical tumor have proved that bortezomib is capable of delaying the tumor growth of multiple myeloma which is suitable for the treatment of multiple myeloma. The above information is edited by the lookchem of Dai Xiongfeng.

Originator

Millenium (LeukoSite, Proscript) (US)

Pharmaceutical Applications

Bortezomib belong to the class of drugs called proteasome inhibitors and is licensed in the United States and the United Kingdom for the treatment of multiple myeloma. The drug has been licensed for patients in whom the myeloma has progressed despite prior treatment or where a bone marrow transplant is not possible or was not successful. It is marketed under the name Velcade? or Cytomib?. Velcade is administered via injection and is sold as powder for reconstitution. Bortezomib was the first drug approved in the new drug class of proteasome inhibitors and boron seems to be its active element. For the mode of action, it is believed that the boron atom binds with high affinity and specificity to the catalytic site of 26S proteasome and inhibits its action. Therapy with Bortezomib can lead to a variety of adverse reactions, including peripheral neuropathy, myelosuppression, renal impairment and gastrointestinal (GI) disturbances together with changes in taste. Nevertheless, the side effects are in most cases less severe than with alternative treatment options such as bone marrow transplantation.

Biochem/physiol Actions

Cell permeable: yes

Clinical Use

Proteasome inhibitor: Treatment of multiple myeloma for people who have already tried at least 1 prior therapy and have disease progression

Synthesis

Although the synthesis of dipeptidyl boronic acids have appeared on several reports, the synthetic details for bortezomib were not revealed. The synthetic route for the preparation of bortezomib is depicted in the scheme.The pinanediol ester of leucine boronic acid (56)was coupled with N-Boc phenylalanine (57) in the presence of TBTU followed by deprotection of the Boc group to provide 58. N-Acylation of 58 then furnished the dipeptide boronate ester 60. Deprotection of the boronic ester functionality was achieved by bi-phase transfer esterification with isobutyl boronic acid. Bortezomib (VI) was isolated by extractive workup.

Drug interactions

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.

Metabolism

In vitro studies with human liver microsomes and human cDNA-expressed cytochrome P450 isozymes indicate that bortezomib is primarily oxidatively metabolised via cytochrome P450 enzymes, 3A4, 2C19, and 1A2. The major metabolic pathway is deboronation to form two deboronated metabolites that subsequently undergo hydroxylation to several metabolites. Deboronated-bortezomib metabolites are inactive as 26S proteasome inhibitors.

References

1) Adams et al. (1999), Proteasome inhibitors: a novel class of potent and effective antitumor agents; Cancer Res., 59 2615 2) Williams et al. (2003), Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts; Mol. Cancer Ther., 2 835 3) Richardson et al. (2003), Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers; Cancer Control, 10 361 4) Herve and Ibrahim (2017), Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia; Neurobiol. Dis., 103 113

Check Digit Verification of cas no

The CAS Registry Mumber 179324-69-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,3,2 and 4 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 179324-69:
(8*1)+(7*7)+(6*9)+(5*3)+(4*2)+(3*4)+(2*6)+(1*9)=167
167 % 10 = 7
So 179324-69-7 is a valid CAS Registry Number.
InChI:InChI=1/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1

179324-69-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Bortezomib

1.2 Other means of identification

Product number -
Other names VELCADE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:179324-69-7 SDS

179324-69-7Synthetic route

dihydroxy-methyl-borane
13061-96-6

dihydroxy-methyl-borane

bortezomib pinacol ester
1029701-48-1

bortezomib pinacol ester

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In water; acetone at 20℃;94%
N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide
205393-22-2

N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide

dihydroxy-methyl-borane
13061-96-6

dihydroxy-methyl-borane

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In water; acetone at 20℃; for 40h;92%
C24H33BN4O4

C24H33BN4O4

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; 2-methyl-propan-1-ol In methanol; pentane at 0 - 20℃; for 12h; Large scale;86%
C26H37BN4O4

C26H37BN4O4

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; 2-methyl-propan-1-ol In methanol; pentane at 0 - 20℃; for 12h; Large scale;86%
(2S)-N-[(1R)-1-(1,3,6,2-dioxazaborocan-2-yl)-3-methylbutyl]-3-phenyl-2-(pyrazin-2-ylformamido)propanamide

(2S)-N-[(1R)-1-(1,3,6,2-dioxazaborocan-2-yl)-3-methylbutyl]-3-phenyl-2-(pyrazin-2-ylformamido)propanamide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In methanol; water at 20℃;82.3%
C25H35BN4O4

C25H35BN4O4

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; 2-methyl-propan-1-ol In methanol; pentane at 0 - 20℃; for 12h; Large scale;82%
N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide
205393-22-2

N-[(1S)-1[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-benzyl]2-pyrazine carboxamide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; Dihydroxy-isobutyl-boran In water at 20℃; Solvent; Temperature;77%
With hydrogenchloride; Dihydroxy-isobutyl-boran In methanol; n-heptane; water at 25 - 30℃; for 1 - 2h; Product distribution / selectivity;70%
With hydrogenchloride; Dihydroxy-isobutyl-boran; water In methanol; hexane at 20℃; for 18h;56.4%
Dihydroxy-isobutyl-boran
84110-40-7

Dihydroxy-isobutyl-boran

C29H39BN4O4

C29H39BN4O4

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In methanol; n-heptane; water at 0 - 25℃; for 2h;71.5%
2-pyrazylcarboxylic acid
98-97-5

2-pyrazylcarboxylic acid

N-benzyl-L-phenylalanine
19461-04-2

N-benzyl-L-phenylalanine

(R)-1-amino-3-methylbutylboronic acid pinanediol ester hydrochloride

(R)-1-amino-3-methylbutylboronic acid pinanediol ester hydrochloride

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Stage #1: N-benzyl-L-phenylalanine; (R)-1-amino-3-methylbutylboronic acid pinanediol ester hydrochloride With 4-methyl-morpholine; N-ethyl-N,N-diisopropylamine; isobutyryl chloride In tetrahydrofuran at 55℃; for 2h; pH=10; Inert atmosphere;
Stage #2: With palladium on activated charcoal; hydrogen In tetrahydrofuran at 68℃; under 4560.31 Torr; for 2h;
Stage #3: 2-pyrazylcarboxylic acid Concentration; Temperature; Solvent; pH-value; Pressure; Further stages;
67%
2-pyrazylcarboxylic acid
98-97-5

2-pyrazylcarboxylic acid

C23H27BNO5Pol

C23H27BNO5Pol

N-Fmoc L-Phe
35661-40-6

N-Fmoc L-Phe

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Stage #1: C23H27BNO5Pol With piperidine In N,N-dimethyl-formamide for 0.333333h; 1-glycerol polystyrene resin;
Stage #2: N-Fmoc L-Phe With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide for 2h; 1-glycerol polystyrene resin;
Stage #3: 2-pyrazylcarboxylic acid Further stages;
54%
(S)-N-(1-(isopentylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide

(S)-N-(1-(isopentylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide

phenylboronic acid
98-80-6

phenylboronic acid

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Stage #1: (S)-N-(1-(isopentylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide With [Rh(OH)(cod)]2; 4-((2'-((triisopropylsilyl)oxy)-[1,1'-binaphthalen]-2-yl)oxy)dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine; bis(pinacol)diborane In acetonitrile at 80℃; for 36h; Inert atmosphere; Sealed tube;
Stage #2: phenylboronic acid With hydrogenchloride In methanol; water; pentane at 20℃; for 12h; Inert atmosphere; stereoselective reaction;
53%
bortezomib pinacol ester
1029701-48-1

bortezomib pinacol ester

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; 2-methyl-propan-1-ol In methanol; pentane at 0 - 20℃; for 12h;52%
With hydrogenchloride In methanol; pentane for 20h;93.4 mg
Stage #1: bortezomib pinacol ester With hydrogenchloride; Dihydroxy-isobutyl-boran In methanol; n-heptane; water at 20℃;
Stage #2: With sodium hydroxide In water
With hydrogenchloride; Dihydroxy-isobutyl-boran
2-pyrazylcarboxylic acid
98-97-5

2-pyrazylcarboxylic acid

(CH3)2CHCH2CH(BO2C2(CH3)4)NHCOCH(CH2C6H5)NH3(1+)*Cl(1-)=(CH3)2CHCH2CH(BO2C2(CH3)4)NHCOCH(CH2C6H5)NH3Cl
1029701-41-4

(CH3)2CHCH2CH(BO2C2(CH3)4)NHCOCH(CH2C6H5)NH3(1+)*Cl(1-)=(CH3)2CHCH2CH(BO2C2(CH3)4)NHCOCH(CH2C6H5)NH3Cl

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine In not given 1. (2-pyrazine)CO2H, TBTU, i-Pr2EtN, 0°C - room temp.; 2. i-BuB(OH)2, pentane, MeOH, 1 N HCl;
(2S)-N-[1-(1,3,6,2-dioxazaborocan-2-yl)-3-methylbutyl]-3-phenyl-2-(pyrazin-2-ylformamido)propanamide

(2S)-N-[1-(1,3,6,2-dioxazaborocan-2-yl)-3-methylbutyl]-3-phenyl-2-(pyrazin-2-ylformamido)propanamide

A

[(1S)-1-[[(2S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]-1-oxopropyl]amino]-3-methylbutyl]boronic acid
1132709-14-8

[(1S)-1-[[(2S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]-1-oxopropyl]amino]-3-methylbutyl]boronic acid

B

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In methanol; water at 20℃;
C32H43BN2O5

C32H43BN2O5

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydrogen; palladium 10% on activated carbon / N,N-dimethyl-formamide
2: N-ethyl-N,N-diisopropylamine / dichloromethane
3: methanol / Acidic conditions
View Scheme
N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}phenylalanine amide
789472-91-9

N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}phenylalanine amide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N-ethyl-N,N-diisopropylamine / dichloromethane
2: methanol / Acidic conditions
View Scheme
N-Cbz-L-Phe
1161-13-3

N-Cbz-L-Phe

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane
2: hydrogen; palladium 10% on activated carbon / N,N-dimethyl-formamide
3: N-ethyl-N,N-diisopropylamine / dichloromethane
4: methanol / Acidic conditions
View Scheme
2-pyrazylcarboxylic acid
98-97-5

2-pyrazylcarboxylic acid

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: thionyl chloride / toluene / 75 °C
2.1: sodium carbonate / toluene; water / 10 - 25 °C
3.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / -40 - -11 °C
4.1: hydrogenchloride; Dihydroxy-isobutyl-boran / water; methanol; n-heptane / 20 °C
4.2: 20 °C
5.1: hydrogenchloride / water; methanol / 20 °C
View Scheme
Multi-step reaction with 4 steps
1.1: 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / tetrahydrofuran / 0.67 h / 0 °C
1.2: 3 h / 0 - 20 °C
2.1: sodium hydroxide / water; acetone / 2 h / 0 °C
3.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 3 h / -10 - -5 °C
4.1: hydrogenchloride / water; acetone / 20 °C
View Scheme
Multi-step reaction with 4 steps
1.1: 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / tetrahydrofuran / 0.67 h / 0 °C
1.2: 3 h / 0 - 20 °C
2.1: sodium hydroxide / water; acetone / 2 h / 0 °C
3.1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 3 h / -10 - -5 °C
4.1: hydrogenchloride / water; acetone / 40 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: hydrogenchloride
2: hydrogenchloride; Dihydroxy-isobutyl-boran
View Scheme
Multi-step reaction with 4 steps
1: triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 20 °C
2: sodium hydroxide / methanol; water / 20 °C
3: triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / dichloromethane / 20 °C
4: Dihydroxy-isobutyl-boran; hydrogenchloride / water; methanol; ethyl acetate
View Scheme
(3aS,4S,6S,7aR)-2-(1-chloro-3-methylbutyl)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole

(3aS,4S,6S,7aR)-2-(1-chloro-3-methylbutyl)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: hexane / -70 - 20 °C / Large scale
2: di-isopropyl ether / 2 h / -10 - 0 °C / Large scale
3: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
4: hydrogenchloride / toluene / 1 h / 0 °C / Large scale
5: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
6: hydrogenchloride; Dihydroxy-isobutyl-boran / hexane; 1,1,1-trideuteromethanol; water / 0 - 20 °C / Large scale
View Scheme
1,1,1-trimethyl-N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-N-(trimethylsilyl)silanamine
514820-48-5

1,1,1-trimethyl-N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-N-(trimethylsilyl)silanamine

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: di-isopropyl ether / 2 h / -10 - 0 °C / Large scale
2: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
3: hydrogenchloride / toluene / 1 h / 0 °C / Large scale
4: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
5: hydrogenchloride; Dihydroxy-isobutyl-boran / hexane; 1,1,1-trideuteromethanol; water / 0 - 20 °C / Large scale
View Scheme
Multi-step reaction with 4 steps
1.1: hydrogenchloride / tert-butyl methyl ether / -40 - 20 °C / Inert atmosphere
2.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / -40 - -11 °C
3.1: hydrogenchloride; Dihydroxy-isobutyl-boran / water; methanol; n-heptane / 20 °C
3.2: 20 °C
4.1: hydrogenchloride / water; methanol / 20 °C
View Scheme
(aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate

(aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
2: hydrogenchloride / toluene / 1 h / 0 °C / Large scale
3: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
4: hydrogenchloride; Dihydroxy-isobutyl-boran / hexane; 1,1,1-trideuteromethanol; water / 0 - 20 °C / Large scale
View Scheme
Multi-step reaction with 3 steps
1.1: dichloromethane / 0.08 h / 0 °C / Inert atmosphere
1.2: 1 h / -3 - 2 °C
1.3: 0.25 h / 15 - 27 °C
2.1: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate / toluene / 0.17 h / Inert atmosphere
2.2: 3 h / 25 °C
3.1: hydrogenchloride; Dihydroxy-isobutyl-boran / methanol; n-heptane / 12 h / 20 °C
View Scheme
tert-butyl [1-({3-methyl-1-[(3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate

tert-butyl [1-({3-methyl-1-[(3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydrogenchloride / toluene / 1 h / 0 °C / Large scale
2: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
3: hydrogenchloride; Dihydroxy-isobutyl-boran / hexane; 1,1,1-trideuteromethanol; water / 0 - 20 °C / Large scale
View Scheme
N-{3-methyl-1-[(3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}phenylalanine amide

N-{3-methyl-1-[(3aS,4S,6S)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}phenylalanine amide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; N-ethyl-N,N-diisopropylamine / dichloromethane / 2 h / 0 - 20 °C / Large scale
2: hydrogenchloride; Dihydroxy-isobutyl-boran / hexane; 1,1,1-trideuteromethanol; water / 0 - 20 °C / Large scale
View Scheme
N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-Nα-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide

N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-Nα-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; Dihydroxy-isobutyl-boran In hexane; 1,1,1-trideuteromethanol; water at 0 - 20℃; Concentration; Temperature; Large scale;
N-tert-butoxycarbonyl-L-phenylalanine
13734-34-4

N-tert-butoxycarbonyl-L-phenylalanine

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: dichloromethane / 0.08 h / 0 °C / Inert atmosphere
1.2: 1 h / -3 - 2 °C
1.3: 0.25 h / 15 - 27 °C
2.1: O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate / toluene / 0.17 h / Inert atmosphere
2.2: 3 h / 25 °C
3.1: hydrogenchloride; Dihydroxy-isobutyl-boran / methanol; n-heptane / 12 h / 20 °C
View Scheme
Multi-step reaction with 4 steps
1: N-isopropylethylamine; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate / acetonitrile / 2 h / -10 - 5 °C
2: dichloromethane / 25 - 35 °C
3: N-ethyl-N,N-diisopropylamine; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate / acetonitrile / 0 - 10 °C
4: Dihydroxy-isobutyl-boran; hydrogenchloride / water / 20 °C
View Scheme
(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid
114457-94-2

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide / 0.33 h / 20 °C / Inert atmosphere
1.2: 4 h / 20 °C / Inert atmosphere
2.1: hydrogenchloride; Dihydroxy-isobutyl-boran / n-heptane; water; methanol / 1.5 h / 20 - 30 °C
View Scheme
Multi-step reaction with 3 steps
1.1: N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate / N,N-dimethyl-formamide / -40 - -11 °C
2.1: hydrogenchloride; Dihydroxy-isobutyl-boran / water; methanol; n-heptane / 20 °C
2.2: 20 °C
3.1: hydrogenchloride / water; methanol / 20 °C
View Scheme
Multi-step reaction with 2 steps
1: N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / dichloromethane / 3 h / -10 - -5 °C
2: hydrogenchloride / water; acetone / 20 °C
View Scheme
(R)-boroleu-(+)-pinanediol trifluoroacetic acid

(R)-boroleu-(+)-pinanediol trifluoroacetic acid

velcade
179324-69-7

velcade

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide / 0.33 h / 20 °C / Inert atmosphere
1.2: 4 h / 20 °C / Inert atmosphere
2.1: hydrogenchloride; Dihydroxy-isobutyl-boran / n-heptane; water; methanol / 1.5 h / 20 - 30 °C
View Scheme
N-((2S)-1-((3-methyl-1-((3aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide

N-((2S)-1-((3-methyl-1-((3aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride; Dihydroxy-isobutyl-boran In methanol; n-heptane; water at 20 - 30℃; for 1.5h;4.2 g
acetone
67-64-1

acetone

phenylboronic acid
98-80-6

phenylboronic acid

velcade
179324-69-7

velcade

Conditions
ConditionsYield
With hydrogenchloride In hexane; acetonitrile
velcade
179324-69-7

velcade

Pyrazine-2-carboxylic acid [(S)-1-((R)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide
289472-78-2

Pyrazine-2-carboxylic acid [(S)-1-((R)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide

Conditions
ConditionsYield
With dihydrogen peroxide In ethanol; water at 20℃; for 1h; Oxidation; hydrolysis;100%
With hydrogenchloride; oxygen In ethanol; water at 25℃; for 336h; pH=2.8; Kinetics; Product distribution; Further Variations:; with/without ascorbic acid; Oxidation; hydrolysis;
With oxygen In ethanol; water at 25℃; for 5844h; pH=6.9; Kinetics; Product distribution; Further Variations:; with/without EDTA; Oxidation; hydrolysis;
C16H29N3O4

C16H29N3O4

velcade
179324-69-7

velcade

C35H50BN7O6

C35H50BN7O6

Conditions
ConditionsYield
In chloroform-d1 at 45℃;95%
pinanediol

pinanediol

velcade
179324-69-7

velcade

C29H39BN4O4

C29H39BN4O4

Conditions
ConditionsYield
In toluene for 3h; Inert atmosphere; Reflux;91.2%
dopamine folic acid

dopamine folic acid

velcade
179324-69-7

velcade

C46H49BN12O9

C46H49BN12O9

Conditions
ConditionsYield
In dimethyl sulfoxide at 25℃;80%
velcade
179324-69-7

velcade

bortezomib
390800-88-1

bortezomib

Conditions
ConditionsYield
In isopropyl alcohol; acetonitrile at 20℃; for 4h; Product distribution / selectivity;76.9%
citric acid
77-92-9

citric acid

velcade
179324-69-7

velcade

5-(carboxymethyl)-2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

5-(carboxymethyl)-2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

Conditions
ConditionsYield
In ethyl acetate at 20 - 74℃; for 3h;71.1%
C14H29N3O6

C14H29N3O6

velcade
179324-69-7

velcade

C33H50BN7O8

C33H50BN7O8

Conditions
ConditionsYield
In chloroform-d170%
velcade
179324-69-7

velcade

A

Pyrazine-2-carboxylic acid ((S)-1-carbamoyl-2-phenyl-ethyl)-amide

Pyrazine-2-carboxylic acid ((S)-1-carbamoyl-2-phenyl-ethyl)-amide

B

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid
114457-94-2

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid

Conditions
ConditionsYield
With sodium hydroxide; oxygen In dimethyl sulfoxide at 70℃; for 250h; pH=12.0; Kinetics; Product distribution; Oxidation; hydrolysis;
With sodium hydroxide; oxygen at 70℃; for 48h; pH=12; Oxidation; hydrolysis;
velcade
179324-69-7

velcade

A

Pyrazine-2-carboxylic acid ((S)-1-carbamoyl-2-phenyl-ethyl)-amide

Pyrazine-2-carboxylic acid ((S)-1-carbamoyl-2-phenyl-ethyl)-amide

B

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid
114457-94-2

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid

C

Pyrazine-2-carboxylic acid [(S)-1-((R)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide
289472-78-2

Pyrazine-2-carboxylic acid [(S)-1-((R)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide

D

Pyrazine-2-carboxylic acid [(S)-1-((S)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide

Pyrazine-2-carboxylic acid [(S)-1-((S)-1-hydroxy-3-methyl-butylcarbamoyl)-2-phenyl-ethyl]-amide

Conditions
ConditionsYield
With dihydrogen peroxide In water at 20℃; for 1h; Kinetics; Product distribution; Further Variations:; Solvents; Oxidation; hydrolysis;
velcade
179324-69-7

velcade

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid
114457-94-2

(S)-3-phenyl-2-[(pyrazine-2-carbonyl)amino]propanoic acid

Conditions
ConditionsYield
With hydrogenchloride; oxygen In dimethyl sulfoxide at 70℃; for 250h; pH=1.0; Kinetics; Product distribution; Oxidation; hydrolysis;
With hydrogenchloride; oxygen at 70℃; for 120h; pH=1.0; Oxidation; hydrolysis;
dopamine hydrochloride
62-31-7

dopamine hydrochloride

velcade
179324-69-7

velcade

C27H33BN5O5(1-)*H(1+)

C27H33BN5O5(1-)*H(1+)

Conditions
ConditionsYield
With sodium dihydrogenphosphate; sodium hydroxide In dimethylsulfoxide-d6; water-d2 for 1h; pH=7.4;

179324-69-7Relevant articles and documents

Discovery of Novel Peptidomimetic Boronate ClpP Inhibitors with Noncanonical Enzyme Mechanism as Potent Virulence Blockers in Vitro and in Vivo

Ju, Yuan,He, Lihui,Zhou, Yuanzheng,Yang, Tao,Sun, Ke,Song, Rao,Yang, Yang,Li, Chengwei,Sang, Zitai,Bao, Rui,Luo, Youfu

, p. 3104 - 3119 (2020/03/04)

Caseinolytic protease P (ClpP) is considered as a promising target for the treatment of Staphylococcus aureus infections. In an unbiased screen of 2632 molecules, a peptidomimetic boronate, MLN9708, was found to be a potent suppressor of SaClpP function. A time-saving and cost-efficient strategy integrating in silico position scanning, multistep miniaturized synthesis, and bioactivity testing was deployed for optimization of this hit compound and led to fast exploration of structure-activity relationships. Five of 150 compounds from the miniaturized synthesis exhibited improved inhibitory activity. Compound 43Hf was the most active inhibitor and showed reversible covalent binding to SaClpP while did not destabilize the tetradecameric structure of SaClpP. The crystal structure of 43Hf-SaClpP complex provided mechanistic insight into the covalent binding mode of peptidomimetic boronate and SaClpP. Furthermore, 43Hf could bind endogenous ClpP in S. aureus cells and exhibited significant efficacy in attenuating S. aureus virulence in vitro and in vivo.

Asymmetric Synthesis of α-Aminoboronates via Rhodium-Catalyzed Enantioselective C(sp3)-H Borylation

Reyes, Ronald L.,Sato, Miyu,Iwai, Tomohiro,Sawamura, Masaya

supporting information, p. 589 - 597 (2020/01/22)

α-Aminoboronic acids, isostructural boron analogues of α-amino acids, have received much attention because of the important biomedical applications implicated for compounds containing this structure. Additionally, the inherent versatility of α-aminoboronic acids as synthetic intermediates through diverse carbon-boron bond transformations makes the efficient synthesis of these compounds highly desirable. Here, we present a Rh-monophosphite chiral catalytic system that enables a highly efficient enantioselective borylation of N-adjacent C(sp3)-H bonds for a range of substrate classes including 2-(N-alkylamino)heteroaryls and N-alkanoyl- or aroyl-based secondary or tertiary amides, some of which are pharmaceutical agents or related compounds. Various stereospecific transformations of the enantioenriched α-aminoboronates, including Suzuki-Miyaura coupling with aryl halides and the Rh-catalyzed reaction with an isocyanate derivative of α-amino acid, affording a new peptide chain elongation method, have been demonstrated. As a highlight of this work, the borylation protocol was successfully applied to the catalyst-controlled site-selective and stereoselective C(sp3)-H borylation of an unprotected dipeptidic compound, allowing remarkably streamlined synthesis of the anti-cancer drug molecule bortezomib and offering a straightforward route for the synthesis of privileged molecular architectures.

Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids

Hinkes, Stefan P.A.,Klein, Christian D.P.

supporting information, p. 3048 - 3052 (2019/05/10)

Boronic acids are an increasingly important compound class for many applications, including C-C bond formation reactions, medicinal chemistry, and diagnostics. The deprotection of boronic ester intermediates is frequently a problematic and inefficient step in boronic acid syntheses. We describe an approach that highly facilitates this transformation by leveraging the volatility of methylboronic acid and its diol esters. The method is performed under mild conditions, provides high yields, and eliminates cumbersome and problematic purification steps.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 179324-69-7